GPIHBP1 is a GPI-anchored endothelial protein essential for triglyceride metabolism that mediates lipoprotein lipase (LPL) transport from the basolateral to apical surface of capillary endothelial cells, thereby anchoring LPL in the capillary lumen where it processes triglyceride-rich lipoproteins 1. GPIHBP1 stabilizes LPL structure and activity, protecting it against ANGPTL4-mediated unfolding 2. The protein also binds chylomicrons and HDL particles, playing a critical role in lipolytic processing and lipid homeostasis 1. Loss-of-function GPIHBP1 mutations cause familial chylomicronemia syndrome with severe hypertriglyceridemia and acute pancreatitis risk 34. Notably, GPIHBP1 autoantibodies represent an acquired form of chylomicronemia by blocking LPL binding and transport, resulting in low plasma LPL levels and elevated triglycerides 5. Recent evidence demonstrates that liver-targeted LPL expression can therapeutically reduce hypertriglyceridemia and pancreatitis severity in GPIHBP1-deficient models, suggesting novel treatment approaches 6. GPIHBP1 expression is enriched in acinar-specific pancreatic endothelial cells, indicating tissue-specific metabolic functions 7.